Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is progressing with a steady OPEX base in line with our expectations. Spago Nanomedical is on track to provide a study update before mid-2024. We look forward to the next update later in May. Tumorad (177Lu-SN201) continues to be supported by the non-clinical program, and in late April, Spago Nanomedical reported favourable data supporting a positive inhibitory effect based on Tumorad as monotherapy.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se